WE-E-BRB-01: Clinical Usage of Knowledge Based Treatment Planning

Authors


Abstract

The knowledge-based treatment planning automation has evolved from academic research from the clinical application with the involvement of the major industry TPS vendors. Previous work proved the concept that IMRT or VMAT plans can be designed without or with minimal human intervention. Recently, the major industry vendors start releasing the automatic planning product such as Philips automatic treatment planning, Varian's Rapidplan, and RaySearch's autoplan. Many centers start to evaluate and use the automatic planning products from TPS vendors. It is more and more becoming evident that automatic planning will be routinely used in the clinic.

The first presentation will focus on the knowledge modeling for clinical treatment planning. The presenter will introduce the algorithm and theory for developing the dose volume histogram (DVH) model, summarize the results on the validation of the DVH model, and discuss the application of DVH for the automatic treatment planning. The second presenter will focus on the clinical use of the automatic treatment planning. The presenter will give an overview of the several automatic treatment planning tools including the tools developed commercially and in-house, present the early experience of using those tools, and discuss the application of the tools in the routine clinical use and in the quality control of the treatment planning.

Learning Objectives:

  • 1.Describe the algorithm and theory behind the knowledge based treatment planning automation.
  • 2.Clinical experience of using automatic planning in clinical trial and patient treatment
  • 3.Early clinical experience of using commercial automatic planning approach
  • 4.The application of automatic planning approach to perform quality assurance of treatment plan.

XD obtain the research funding from Varian Medical System, Philips Medical System and Funding support form Sister Institution Network Fund of MD Anderson, XD is also a founder of Global Oncology One

Ancillary